Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information


Hayward, USA
24650 Industrial Boulevard
Hayward, CA, 94545


Chairman of the Board, President & CEO
Vice President, Development and Manufacturing
Vice President, Commercial Operations
Vice President, General Counsel, Corporate Secretary
Boards of Director
Board of Directors
Board of Directors
Board of Directors
Show All People


Series B, 3/2007
New Leaf Venture Partners
Quilvest Ventures
New Enterprise Associates
Alta Partners
Omega Funds
Series B, 1/2010
Venture Round, 5/2010
Series B, 9/2010
New Leaf Venture Partners
New Enterprise Associates
Series C, 11/2012
Private Equity, 4/2014
RA Capital Management
Farallon Capital Management
Foresite Capital
Fred Alger Management
New Leaf Venture Partners
Quilvest Ventures
Debt, 8/2012
Debt, 11/2012
New Enterprise Associates
New Leaf Venture Partners


Intarcia Therapeutics

Intarcia Therapeutics, Inc. is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. The company’s products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. The company was formerly known as BioMedicines, Inc. and changed its name to Intarcia Therapeutics, Inc. in September 2004. Intarcia Therapeutics was founded in 1997 and is based in Hayward, California with an additional office in Mountain View, California.

Recent Milestones




  1. Intarcia restarts with $50M for hepatitis, diabetes treatments ( [edit]
  2. SEC ( [edit]
  3. SEC ( [edit]
  4. Intarcia Therapeutics raises $5M to treat long-term conditions ( [edit]
  5. SEC ( [edit]
  6. Intarcia Therapeutics Secures Landmark $210 Million Financing to Fund Its Global Phase 3 Program for ITCA 650 in Type 2 Diabetes ( [edit]
  7. Intarcia Amasses $210M in Equity, Debt Financing for Type 2 Diabetes Therapy ( [edit]
  8. Intarcia Therapeutics Raises $200m Financing ( [edit]
  9. Intarcia Therapeutics Names Kurt Graves To New Executive Chairman Post ( [edit]
Edit This Page
Last Edited 4/10/14

Revision History RSS Picture


Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API


Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy